Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

被引：38
|
作者：
Isakoff, Steven J. [1 ]
Baselga, Jose [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; PERTUZUMAB; LAPATINIB; EFFICACY; THERAPY; COMPLEX;
D O I：
10.1200/JCO.2010.31.6679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [1] Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 29, pg 351, 2011)
    Isakoff, Steven J.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 353 - 353
  • [2] Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (vol 33, pg 1712, 2015)
    Baselga, J.
    Clark, E.
    Kiermaier, A.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (01) : 54 - 56
  • [4] Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Van den Mooter, Tom
    Teuwen, Laure-Anne
    Rutten, Annemie
    Dirix, Luc
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (05) : 749 - 760
  • [5] Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review
    Mathew, Jacob
    Perez, Edith A.
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 594 - 600
  • [6] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Ke-Da Yu
    Xin Wang
    Wan-Kun Chen
    Lei Fan
    Miao Mo
    Han Chen
    npj Precision Oncology, 4
  • [7] Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Liberato, Nicola Lucio
    Marchetti, Monia
    Barosi, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 625 - 633
  • [8] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Yu, Ke-Da
    Wang, Xin
    Chen, Wan-Kun
    Fan, Lei
    Mo, Miao
    Chen, Han
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [9] Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Spector, Neil L.
    Blackwell, Kimberly L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5838 - 5847
  • [10] Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer
    Sotelo, Miguel J.
    Angel Garcia-Saenz, Jose
    Manso, Luis
    Moreno, Fernando
    Ciruelos, Eva
    Callata, Hector R.
    Mendiola, Cesar
    Cabezas, Santiago
    Ghanem, Ismael
    Diaz-Rubio, Eduardo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (04) : 967 - 972
12345